(Q34209022)

31 July 2017

title

The economic impact of hypertension (English)

1 reference

31 July 2017

1 reference

William J Elliott

1

1 reference

31 July 2017

publication date

1 May 2003

1 reference

Journal of Clinical Hypertension

31 July 2017

published in

1 reference

31 July 2017

volume

5

1 reference

31 July 2017

issue

3 Suppl 2

1 reference

31 July 2017

page(s)

3-13

1 reference

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

The urgent need to improve hypertension care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

Worldwide trends and shortcomings in the treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

Blood pressure, systolic and diastolic, and cardiovascular risks. US population data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

Impact of high-normal blood pressure on the risk of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

Clinical Advisory Statement. Importance of systolic blood pressure in older Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

Failure of evidence-based medicine in the treatment of hypertension in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

Characteristics of patients with uncontrolled hypertension in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

The prevention or delay of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

Hypertension in patients with diabetes. Overcoming barriers to effective control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians' Desk Reference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

The health economics of the treatment of hyperlipidemia and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2003.02463.X

10.1111/J.1524-6175.2003.02463.X

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference